VERTEX PHARMACEUTICALS INC / MA Other Current Liabilities
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Other Current Liabilities of $329.40 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2026-08-04
- 2026-06-30: Other Liabilities, Current $329.40M.
- 2026-03-31: Other Liabilities, Current $407.10M.
- 2025-12-31: Other Liabilities, Current $428.30M.
- 2025-09-30: Other Liabilities, Current $441.50M.
| Period end | Other Liabilities, Current | Other Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $329.40M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $407.10M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $428.30M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $441.50M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $425.40M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $386.40M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $363.00M 10-K · filed 2026-02-13 | |
| 2024-09-30 | $357.60M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $279.30M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $648.60M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $527.20M 10-K · filed 2025-02-13 | |
| 2023-09-30 | $316.20M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $391.00M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $377.00M 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $311.50M 10-K · filed 2024-02-15 | |
| 2022-09-30 | $218.00M 10-Q · filed 2022-10-28 | |
| 2022-06-30 | $238.70M 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $286.10M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $268.40M 10-K · filed 2023-02-10 | |
| 2021-09-30 | $201.41M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $226.36M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $284.17M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $317.40M 10-K · filed 2022-02-09 | $317.42M 10-K · filed 2021-02-11 |
| 2020-09-30 | $192.54M 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $151.78M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $179.78M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $130.31M 10-K · filed 2021-02-11 | |
| 2019-09-30 | $122.58M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $113.10M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $108.76M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $50.41M 10-K · filed 2020-02-13 | $40.59M 10-K · filed 2019-02-13 |
| 2018-09-30 | $60.36M 10-Q · filed 2018-10-25 | |
| 2018-06-30 | $59.63M 10-Q · filed 2018-07-26 | |
| 2018-03-31 | $56.65M 10-Q · filed 2018-04-27 | |
| 2018-01-01 | $36.46M 10-K · filed 2019-02-13 | |
| 2017-12-31 | $34.37M 10-K · filed 2019-02-13 | $27.03M 10-K · filed 2018-02-15 |
| 2017-09-30 | $27.69M 10-Q · filed 2017-10-30 | |
| 2017-06-30 | $24.77M 10-Q · filed 2017-07-28 | |
| 2017-03-31 | $10.95M 10-Q · filed 2017-04-28 | |
| 2016-12-31 | $10.94M 10-K · filed 2018-02-15 | |
| 2016-09-30 | $51.22M 10-Q · filed 2016-10-31 | |
| 2016-06-30 | $38.22M 10-Q · filed 2016-08-01 | |
| 2016-03-31 | $18.12M 10-Q · filed 2016-05-03 | |
| 2015-12-31 | $14.37M 10-K · filed 2017-02-23 | |
| 2015-09-30 | $9.53M 10-Q · filed 2015-10-30 | |
| 2015-06-30 | $13.20M 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $4.68M 10-Q · filed 2015-05-04 | |
| 2014-12-31 | $4.80M 10-K · filed 2016-02-16 | |
| 2014-09-30 | $11.71M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $14.44M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $32.47M 10-Q · filed 2014-05-05 | |
| 2013-12-31 | $24.74M 10-K · filed 2015-02-13 | |
| 2013-09-30 | $21.82M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $23.62M 10-Q · filed 2013-08-02 | |
| 2013-03-31 | $25.20M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $19.70M 10-K · filed 2014-02-11 | |
| 2012-09-30 | $13.94M 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $13.35M 10-Q · filed 2012-08-08 | |
| 2011-12-31 | $12.47M 10-K · filed 2013-03-01 | |
| 2011-03-31 | $2.00M 10-Q · filed 2011-05-06 | |
| 2010-12-31 | $6.15M 10-K · filed 2012-02-22 | |
| 2010-09-30 | $8.69M 10-Q · filed 2010-10-28 | |
| 2010-06-30 | $9.00M 10-Q · filed 2010-08-03 | |
| 2010-03-31 | $14.28M 10-Q · filed 2010-05-03 | |
| 2009-12-31 | $15.23M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |